31,4 %The prevalence of polymerase chain reaction-defined SARS-CoV-2 was 31.4% among 277 participants tested in Sindara and Lambaréné, Gabon, from August 2021 to February 2022.
GabonCOVID-19observé August 2021 to February 2022publié 2025The American journal of tropical medicine and hygieneeurope_pmcdocument de 10 observations
4,7 %Co-infection of malaria with filaria prevalence was 4.7% among school-aged children in Gabon.
Gabonfilaria · paludismeobservé 2021publié 2024Tropical medicine and infectious diseaseeurope_pmcdocument de 8 observationsDOI 10.3390/tropicalmed10010011
90,3 %Day 28 PCR-adjusted adequate clinical and parasitological response (ACPR) was 90.3% (28/31) with 400 mg ferroquine plus 300 mg artefenomel.
Gabonpaludismepublié 2023Malaria journaleurope_pmcdocument de 13 observations
Plasmodium falciparum was the only Plasmodium species identified among malaria-infected patients in the study.
Gabonpaludismeobservé 2012publié 2014BioMed research internationaleurope_pmcdocument de 6 observationsDOI 10.1155/2014/351281
19,6 %Oral high-risk (HR) HPV prevalence was 19.6% among 61 unvaccinated men who have sex with men (MSM) taking preexposure prophylaxis (PrEP) in France.
Gabonhigh-risk HPVpublié 2019Open forum infectious diseasesPubMeddocument de 10 observations
13,3 timesInfants born from mothers uncertain about taking prophylactic antiretroviral therapy were 13.3 times more likely to be infected by HIV than infants born from mothers certain about taking prophylactic antiretroviral therapy.
GabonVIH/sidapublié 2018International journal of STD & AIDSPubMeddocument de 5 observations
7,3 %7,3 % des patientes étaient séropositives pour le VIH.
GabonVIH/sidaHAL · Unilimdocument de 322 observations
73 %Unidentified strongyles were identified in 73% of the parasite-positive samples.
Gabonunidentified strongylespublié 2021Veterinary worldeurope_pmcdocument de 14 observations
305 patientsA retrospective survey of 305 patients with COVID-19 found that 279 (92%) were not eligible for a hydroxychloroquine clinical trial mainly due to safety concerns caused by health conditions or co-medications.
GabonCOVID-19publié 2021International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument de 8 observations
23 %Microscopic prevalence of P. falciparum infection in Dienga was 23% in the recent study (n = 370), compared to 7% ten years earlier (n = 323), p < 0.001.
Gabonpaludismepublié 2016PloS oneeurope_pmcdocument de 9 observations
42 %Infant colonization rate peaked at 42% after 1 month.
GabonStaphylococcus aureuspublié 2014Clinical microbiology and infection : the official publication of the European Society of europe_pmcdocument de 5 observationsDOI 10.1111/1469-0691.12417
80 %More than 80% of patients showed at least 50% reduction of Schistosoma haematobium egg excretion.
Gabonschistosomiasepublié 2013Clinical infectious diseases : an official publication of the Infectious Diseases Society europe_pmcdocument de 4 observationsDOI 10.1093/cid/cis976
7,2 nMThe mean concentration required to inhibit 50% of growth (IC50) of Plasmodium malariae with chloroquine was 7.2 nM.
Gabonpaludismepublié 2025Pathogens (Basel, Switzerland)europe_pmcdocument de 4 observations
The prevalence of chronic HBV infection (HBsAg+) seems better controlled before age 16–18 by females infected vertically or horizontally in areas where genotypes B–E are dominant.
Gabonhépatite Bpublié 2022Viruseseurope_pmcdocument de 11 observations
0,317 kappaThe agreement between declarative and pharmacy visit compliance methods for quantitative adherence was fair, with a Kappa value of 0.317.
GabonVIH/sidapublié 2019African journal of AIDS research : AJAReurope_pmcdocument de 6 observations
68 %The PCR-based corrected cure rate was 68%.
Gabonstrongyloidiasispublié 2025Parasitology researcheurope_pmcdocument de 7 observations
3 699 patientsThe study involved 3699 sickle cell disease patients living in Mali, Senegal, Ivory Coast, Democratic Republic of Congo, Gabon and Cameroon.
Cameroun · Côte d'Ivoire · Gabon · Mali · Sénégaldrépanocytosepublié 2024British journal of haematologyeurope_pmcdocument de 10 observations
95 %The specificity of nasal transepithelial potential difference test for the diagnosis of cystic fibrosis was 95%.
Gaboncystic fibrosispublié 1995PubMedOpenAlexdocument de 5 observations
72,7 %Severe anemia was present in 72.7% of severe malaria cases on admission.
Gabonpaludismepublié 2023Malaria journaleurope_pmcdocument de 25 observationsDOI 10.1186/s12936-023-04512-7
112 ml/min/1.73 m²The mean estimated glomerular filtration rate (eGFR) was 112 ± 45.3 ml/min/1.73 m² in children with sickle cell disease.
Gabondrépanocytoseobservé 2022publié 2024International Journal of Contemporary PediatricsOpenAlexdocument de 3 observationsDOI 10.18203/2349-3291.ijcp20241285
68,43 %The pooled sensitivity of real-time PCR for syphilis diagnosis was 68.43%.
Gabonsyphilispublié 2022Sexually transmitted diseaseseurope_pmcdocument de 6 observations
46,2 %La prévalence des parasites du paludisme à forme asexuée chez les enfants positifs uniquement pour P. falciparum était de 46,2 % dans le groupe APOE Ɛ4 (79 sur 171).
GabonpaludismeHAL · Unilimdocument de 81 observations
20,4 %The seroprevalence of hepatitis C virus in Ogooué-Lolo province was 20.4%.
Gabonhépatite Cpublié 2012PLoS ONEOpenAlexdocument de 7 observationsDOI 10.1371/journal.pone.0042002
0,9 %HPV-11 prevalence among HIV-infected women in Ouagadougou was 0.9%.
GabonVIH/sidaobservé 2009–2010publié 2011Acta tropicaeurope_pmcdocument de 8 observations
0,79 AUCSchistosoma haematobium-soluble egg antigen had an area under the curve of 0.79 in urine for diagnosing Schistosoma haematobium infection.
Gabonschistosomiasepublié 2021The Lancet. Microbeeurope_pmcdocument de 7 observationsDOI 10.1016/s2666-5247(21)00150-6
Chaque ligne mène à son document source. Le nombre indiqué est celui des observations VALIDÉES qu'il porte, jamais celui des observations extraites : les deux diffèrent sur la plupart des documents. L'extrait exact du texte source n'est pas publié, par contrainte de droit d'auteur.